MedTrace Logo

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

NCT00776503 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2014-03-20

No results posted yet for this study

Summary

The purpose of this study is to determine the maximum tolerated duration and schedule of oral VORINOSTAT in addition to low dose cytarabine in the treatment of Intermediate-2 and High risk myelodysplastic syndromes.

Conditions

Interventions

DRUG

VORINOSTAT

vorinostat; 400mg once daily; increasing duration (7-10-14 days)

Sponsors & Collaborators

Principal Investigators

  • Thomas PREBET, MD · Groupe Francophone des Myelodysplasies

  • Norbert VEY, MD · Groupe Francophone des Myelodysplasies

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00776503 on ClinicalTrials.gov